ERAS

NEUTRALTechnical

Erasca, Inc.

2026-02-25

Price

$13.46

-1.10%

Score1.5Noise

Signals2/8 DNA0/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

ERAS is undergoing a structural re-rating, transitioning from a 'busted IPO' to a 'platform leader' driven by the Jan 12th ERAS-0015 (molecular glue) data which showed confirmed responses where competitors failed. The recent -1.1% dip is classic 'institutional absorption' following yesterday's (Feb 24) Patent Grant for ERAS-4001; the market treated this IP win as a 'check-the-box' event rather than a volatility trigger. In the current RISK_ON regime, the 'Perfect Stack' technicals confirm that buyers are aggressively defending the $13 level, digesting the recent capital raise (Jan 23) before the next leg up.

Fired Signals

GOLDEN CROSSPERFECT STACKWEAK FINISHEXTENSION

Key Takeaways

**Thesis Pivot:** The Jan 12th data (ERAS-0015) validated the molecular glue approach; yesterday's Patent Grant (Feb 24) secures the moat through 2043, removing long-term IP risk.
**Supply Dynamics:** The stock successfully absorbed the Jan 23rd upsized offering; price holding >$13 (vs. $10 support) signals the 'Smart Money' is locking away shares.
**Execution Risk:** While the 'AI Doom' unwind helps, high-beta biotech remains vulnerable to macro duration shocks; a loss of $10.13 invalidates the breakout.

← Back to 2026-02-25 View Full ERAS History →Yahoo Finance &nearr;